MaxCyte raises full year 2026 revenue guidance
MaxCyte reported preliminary Q3 2026 core revenue up 26% and increased FY 2026 full-year guidance to approximately $34 million, driven by accelerated demand and milestone revenue.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed